Tim Pieters
Impact in
- Hematology top 10%
- Acute Myeloid Leukemia Research
-
- Pluripotent Stem Cells Research
- Wnt/β-catenin signaling in development and cancer
- CRISPR and Genetic Engineering
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
Papers in
-
- Acute Myeloid Leukemia Research 5
-
- Pluripotent Stem Cells Research 8
- CRISPR and Genetic Engineering 7
- Wnt/β-catenin signaling in development and cancer 5
- Cancer-related gene regulation 5
- Epigenetics and DNA Methylation 3
Tim Pieters
24 papers receiving 560 citations
Peers
Comparison fields: 5 of 80
- Hematology 91
- Molecular Biology 421
- Cell Biology 57
- Cancer Research 49
- Oncology 78
Countries citing papers authored by Tim Pieters
This map shows the geographic impact of Tim Pieters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Pieters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Pieters more than expected).
Fields of papers citing papers by Tim Pieters
This network shows the impact of papers produced by Tim Pieters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Pieters. The network helps show where Tim Pieters may publish in the future.
Co-authors
The 25 scholars most cited alongside Tim Pieters, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 19 | |
| 5 | 2023 | 2 | |
| 6 | 2021 | 6 | |
| 7 | 2021 | 2 | |
| 8 | 2020 | 5 | |
| 9 | 2019 | 18 | |
| 10 | 2019 | 4 | |
| 11 | 2017 | 2 | |
| 12 | 2017 | 49 | |
| 13 | 2017 | 46 | |
| 14 | Targeting BET family proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia | 2016 | 1 |
| 15 | 2016 | 7 | |
| 16 | 2016 | 22 | |
| 17 | 2015 | 90 | |
| 18 | 2011 | 17 | |
| 19 | 2011 | 34 | |
| 20 | 2011 | 47 |
About Tim Pieters
Tim Pieters is a scholar working on Hematology, Molecular Biology, Oncology, Public Health, Environmental and Occupational Health and Genetics, having authored 26 papers that have together received 563 indexed citations. Recurring topics across this work include Pluripotent Stem Cells Research (8 papers), CRISPR and Genetic Engineering (7 papers), Acute Lymphoblastic Leukemia research (6 papers), Acute Myeloid Leukemia Research (5 papers), Wnt/β-catenin signaling in development and cancer (5 papers), Cancer-related gene regulation (5 papers), CAR-T cell therapy research (4 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Hematology (91 citations), Molecular Biology (421 citations), Cell Biology (57 citations), Cancer Research (49 citations) and Oncology (78 citations). Tim Pieters has collaborated with scholars based in Belgium, Australia and Germany. Frequent co-authors include Frans van Roy, Steven Goossens, Jody J. Haigh, Pieter Van Vlierberghe, Geert Berx, Filip Matthijssens, Bruce Poppe, Wouter Van Loocke, Sofie Peirs and Lieven Haenebalcke. Their work appears in journals such as Frontiers in bioscience, Science Advances, Blood Advances, Leukemia and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.